Triterpenoid-rich fraction from ilex hainanensis merr. attenuates non-alcoholic fatty liver disease induced by high fat diet in rats

American Journal of Chinese Medicine

Volumn 41, Issue 3, 2013, Pages 487-502

  Cui, Wei Xi ^a   Yang, Jie ^a   Chen, Xiao Qing ^b   Mao, Qian ^a   Wei, Xiang Lan ^c   Wen, Xiao Dong ^a   Wang, Qiang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Xi'An Chest and Tuberculosis Hospital   (China)

Author keywords

Ilex hainanensis Merr; Inflammation; Insulin Resistance; NAFLD Rats; Oxidative Stress; Triterpenoid Rich Fraction

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CYTOCHROME P450 2E1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ILEX HAINANENSIS EXTRACT; INSULIN; LIVER PROTECTIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLANT EXTRACT; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TRITERPENOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HISTOPATHOLOGY; HYPERLIPIDEMIA; ILEX; ILEX HAINANENSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN RESISTANCE; LIVER DYSFUNCTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CYTOCHROME P-450 CYP2E1; DIET, HIGH-FAT; FATTY LIVER; HYPERLIPIDEMIAS; ILEX; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; LIPIDS; LIVER; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878388930     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0192415X13500353     Document Type: Article

References (36)

1. Ahmed, M.H. and C.D. Byrne. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov. Today 12: 740-747, 2007. (Pubitemid 47362786)
2. Bacon, B.R., M.J. Farahvash, C.G. Janney and B.A. Neuschwander-Tetri. Nonalcoholic steatohepatitis: an expended clinical entity. Gastroenterology 107: 1103-1109, 1994. (Pubitemid 24294573)
3. Chalasani, N., J.C. Gorski, M.S. Asghar, A. Asghar, B. Foresman, S.D. Hall and D.W. Crabb. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37: 544-550, 2003. (Pubitemid 36258775)
4. Chen, X.Q., K. Zan, H. Liu, J. Yang, M.X. Lai and Q. Wang. Triterpenes and flavonoids from Ilex hainanensis Merr. (Aquifoliaceae). Biochem. Syst. Ecol. 37: 678-682, 2009.
5. Cortez-Pinto, H. and M.E. Camilo. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract. Res. Clin. Gastroenterol. 18: 1089-1104, 2004. (Pubitemid 39517694)
6. de Luca, C. and J.M. Olefsky. Inflammation and insulin resistance. FEBS Lett. 582: 97-105, 2008. (Pubitemid 50010731)
7. Department of Health of Guangxi Zhuang Minority Autonomous Region. In: Chinese Medicinal Materials Standard of Guangxi, 1990 edition. Guangxi Science and Technology Press, Nanning, 1992, pp. 20-21.
8. Dixon, J.B., P.S. Bhathal, N.R. Hughes and P.E. O'Brien. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39: 1647-1654, 2004. (Pubitemid 38702666)
9. Emanuela, F., M. Grazia, de R. Marco, L. Maria Paola, F. Giorgio and B. Marco. Inflammation as a link between obesity and metabolic syndrome. J. Nutr. Metab. doi:10.1155/2012/476380, 2012.
10. Emery, M.G., J.M. Fisher, J.Y. Chien, E.D. Kharasch, E.P. Dellinger, K.V. Kowdley and K.E. Thummel. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 38: 428-435, 2003. (Pubitemid 36919864)
11. Fang, R.T. and T.S. Wei. Effects of the ethanol extract from Ilex hainanensis Merr. on experimental hyperlipidemia in rats. Northwest. Pharm. J. 26: 123-125, 2011.
12. Harano, Y., K. Yasui, T. Toyama, T. Nakajima, H. Mitsuyoshi, M. Mimani, T. Hirasawa, Y. Itoh and T. Okanoue. Fenofibrate, a peroxisome proliferators-activated receptor-agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver shionogi mice with hereditary fatty liver. Liver Int. 26: 613-620, 2006.
13. Hong, X.Z., L.D. Li and L.M. Wu. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin. Exp. Pharmacol. Physiol. 34: 27-35, 2007. (Pubitemid 46069582)
14. Hu, C.M., Q. Cao, X.W. Lv, W.M. Cheng, R. Li and J. Li. Protective effects of total flavonoids from Litsea coreana on alcoholic fatty liver in rats associated with down-regulation adipose differentiation-related protein expression. Am. J. Chin. Med. 40: 599-610, 2012.
15. Huang, W., J. Yu, X. Jia, L. Xiong, N. Li and X. Wen. Zhenqing recipe improves glucose metabolism and insulin sensitivity by repressing hepatic FOXO1 in type 2 diabetic rats. Am. J. Chin. Med. 40: 721-733, 2012.
16. Kirsch, R., V. Clarkson, E.G. Shephard, D.A. Marais, M.A. Jaffer, V.E. Woodburne, R.E. Kirsch and P. de L. Hall. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18: 1272-1282, 2003. (Pubitemid 37464002)
17. Leclercq, I.A., G.C. Farrell, J. Field, D.R. Bell, F.J. Gonzalez and G.R. Robertson. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105: 1067-1975, 2000.
18. Lee, Y.J., D.H. Choi, E.J. Kim, H.Y. Kim, T.O. Kwon, D.G. Kang and H.S. Lee. Hypotensive, hypolipidemic, and vascular protective effects of Morus alba L. in rats fed an atherogenic diet. Am. J. Chin. Med. 39: 39-52, 2011.
19. Li, J.M. and B.H. Lu. Clinical effects of Shanlvcha on hypertension and hyperlipidemia. Guangxi Med. J. 7: 287-290, 1985.
20. Liu, Y., H.Y. Wei, J.C. Long and Z.O. Jiang. Pharmacodynamics of Shanlucha antihypertension tablets for the treatment of hypertension with vertigo and headache. Chin. J. Exp. Tradit. Med. Formul. 16: 86-87, 2010.
21. Ludwig, J., T.R. Viggiano, D.B. McGill and B.J. Oh. Non-alcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo. Clin. Proc. 55: 434-438, 1980. (Pubitemid 10057164)
22. Matteoni, C.A., Z.M. Younosis, T. Gramlich, N. Boparai, Y.C. Liu and A.J. McCullough. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413-1419, 1999. (Pubitemid 29258890)
23. Medina, J., L.I. Fernández-Salazar, L. García-Buey and R. Moreno-Otero. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 27: 2057-2066, 2004. (Pubitemid 38989257)
24. Ohnishi, R., I. Matsui-Yuasa, Y. Deguchi, K. Yaku, M. Tabuchi, H. Munakata, Y. Akahoshi and A. Kojima-Yuasa. 10-acetoxychavicol acetate inhibits adipogenesis in 3T3-L1 adipocytes and in high fat-fed rats. Am. J. Chin. Med. 40: 1189-1204, 2012.
25. Salt, W.B. 2nd. Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. J. Insur. Med. 36: 27-41, 2004.
26. Seo, Y.S., J.H. Kim, N.Y. Jo, K.M. Choi, S.H. Baik, J.J. Park, J.S. Kim, K.S. Byun, Y.T. Bak, C.H. Lee, A.R. Kim and J.E. Yeon. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Hepatology 23: 102-109, 2008. (Pubitemid 350265194)
27. Taskinen, M.R. Diabetic dyslipidaemia: from basic research to clinic practice. Diabetologia 46: 733-749, 2003.
28. Tilg, H. and G.S. Hotamisligil. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 131: 934-945, 2006. (Pubitemid 44307061)
29. Tsai, J.C., W.H. Peng, T.H. Chiu, S.C. Lai and C.Y. Lee. Anti-inflammatory effects of Scoparia dulcis L. and betulinic acid. Am. J. Chin. Med. 39: 943-956, 2011.
30. Wei, J. and Y. Sun. Effect of hainan holly leaf total flavonoids on serum lipids based on hyperlipidemia mice. J. Yangzhou Univ. (Agric. Life Sci. ed.) 30: 64-70, 2009.
31. Wei, X.L., X.Q. Chen, R.T. Fang, X.Y. Sun, C.S. Zhu, J. Yang, X. Xue and Q. Wang. Preventive effects of flavonoid extracts from Ilex hainanensis Merr. on rats with hepatic steatosis induced by a high-fat diet. Drug Develop. Res. 73: 308-316, 2012.
32. Weltman, M.D., G.C. Farrell, P. Hall, M. Ingelman-Sundberg and C. Liddle. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27: 128-133, 1998. (Pubitemid 28041545)
33. Xu, R.Y., Y.P. Hong, X.C. Shangguan, Z.P. Yin, Y. Jiang and M.S. Chen. Determination of total triterpene saponins in Cyclocarya paliurus (Batal.) Iljinskaja by sprctrophotometry. Acta Agric. Univ. Jiangxi 29: 449-453, 2007.
34. Yki-Järvinen, H. Ectopic fat accumulation: an important cause of insulin resistance in humans. J. R. Soc. Med. 42: 39-45, 2002. (Pubitemid 34879130)
35. Zambon, A., P. Gervois, P. Pauletto, J.C. Fruchart and B. Staels. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-acticators clinical and experimental evidence. Arterioscler. Thromb. Vasc. Biol. 26: 977-986, 2006. (Pubitemid 43732101)
36. Zhou, S.X., J.S. Yang, F.C. Liu and P.F. Tu. Triterpenoids from the leaves of Ilex hainanensis. Helv. Chim. Acta 90: 121-126, 2007.